Gilead Sciences Inc has priced its Covid-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid, according to Reuters.
The price tag is below the $5,080 per course recommendation by US drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week.
But it is more in line with a lower range suggested by ICER of around $2,520 to $2,800, if cheap steroid dexamethasone, which is not patent protected, is cleared for use in Covid-19.
Read full story here.
